Data / Drug companies / Fosaprepitant
Fosaprepitant: 10 companies and 14 products in the FDA NDC directory
Fosaprepitant is listed in the FDA National Drug Code Directory by 10 companies, with 14 products in commercial distribution. 12 of the products (85.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, powder, lyophilized, for solution, and the newest product started marketing on July 23, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 10
- Products
- 14
- Generic (ANDA) products
- 12 (85.7%)
- Application numbers
- 8
- Routes
- Intravenous
- Brand names
- Navitrux
- openFDA record search
- api.fda.gov
Companies that list fosaprepitant
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Dr. Reddy's Laboratories Inc. | 3 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | February 12, 2026 |
| BluePoint Laboratories | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 15, 2025 |
| Novadoz Pharmaceuticals LLC | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 12, 2020 |
| Actavis Pharma, Inc. | 1 | injection, powder, lyophilized, for solution | New drug applications (NDA) | September 19, 2019 |
| Avyxa Pharma, LLC | 1 | injection, powder, lyophilized, for solution | New drug applications (NDA) | July 23, 2026 |
| Be Pharmaceuticals Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 15, 2019 |
| Bryant Ranch Prepack | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 12, 2020 |
| Fresenius Kabi USA, LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 5, 2019 |
| Mylan Institutional LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 5, 2019 |
| NorthStar RxLLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 5, 2019 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, lyophilized, for solution | 14 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 12 | 85.7% |
| New drug applications (NDA) | 2 | 14.3% |
Pharmacologic classes
| Class | Products |
|---|---|
| Substance P/Neurokinin-1 Receptor Antagonist | 14 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.